{
    "id": "034552a5-bc13-423a-951c-893e9f60c648",
    "indications": "Depakote is an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar disorder ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 )",
    "contraindications": "Depakote tablets are intended for oral administration. Depakote tablets should be swallowed whole and should not be crushed or chewed. \n                  Patients should be informed to take Depakote every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.",
    "warningsAndPrecautions": "Depakote tablets (divalproex sodium delayed-release tablets) are supplied as: \n                  125 mg salmon pink-colored tablets: \n                  \n                     Bottles of 100, tablets with the “a” logo and the code NT – NDC 0074-6212-13\n                     \n                     Bottles of 100, tablets with the code NT – NDC 0074-7325-13\n                  \n                  250 mg peach-colored tablets: \n                  \n                     Bottles of 100, tablets with the “a” logo and the code NR – NDC 0074-6214-13\n                     \n                     Bottles of 100, tablets with the code NR – NDC 0074-7326-13\n                  \n                  500 mg lavender-colored tablets: \n                  \n                     Bottles of 100, tablets with the “a” logo and the code NS – NDC 0074-6215-13\n                     \n                     Bottles of 100, tablets with the code NS – NDC 0074-7327-13\n                  \n                  Recommended Storage: Store tablets below 86°F (30°C).",
    "adverseReactions": "Depakote is contraindicated in patients:\n                  • with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ]. \n                  • known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ]. \n                  \n                     • with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid.  Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions \n                        (\n                        \n                           5.12\n                        \n                        , \n                        \n                           5.13\n                        \n                        , \n                        \n                           5.14\n                        \n                        )\n                        ]. \n                  \n                  • with known urea cycle disorders [see Warnings and Precautions \n                     (\n                     \n                        5.6\n                     \n                     )\n                     ]. \n                  • being treated for prophylaxis of migraine headaches who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions \n                     (\n                     \n                        5.2\n                     \n                     , \n                     \n                        5.3\n                     \n                     , \n                     \n                        5.4\n                     \n                     )\n                      and Use in Specific Populations \n                     (\n                     \n                        8.1\n                     \n                     )\n                     ].",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "DIACETYLATED MONOGLYCERIDES",
            "code": "5Z17386USF"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "organization": "AbbVie Inc.",
    "name": "Depakote",
    "effectiveTime": "20250509"
}